HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lumiracoxib.

Abstract
Lumiracoxib is a highly selective and potent cyclo-oxygenase (COX)-2 inhibitor, with a novel structure that conveys weakly acidic properties and a unique pharmacological profile. It is rapidly absorbed, with a relatively short plasma half-life. In well designed clinical trials of 1-52 weeks' duration in patients with osteoarthritis (OA) or rheumatoid arthritis, the efficacy of oral lumiracoxib 100-400 mg/day in decreasing pain intensity and improving functional status was greater than that with placebo and similar to those with nonselective NSAIDs or celecoxib 200mg once daily. In single- and multiple-dose well designed trials in patients with acute pain associated with primary dysmenorrhoea, dental or orthopaedic surgery or tension-type headache, lumiracoxib 100-800 mg once daily was more effective in relieving acute pain than placebo or controlled-release oxycodone 20 mg, and was at least as effective as selective COX-2 inhibitors or nonselective NSAIDs. Lumiracoxib was generally well tolerated in clinical trials, with a similar overall tolerability profile to those of placebo and other COX-2-selective inhibitors. In a large 52-week safety trial in patients with OA, lumiracoxib 400mg once daily had a rate of gastrointestinal ulcer complications that was approximately one-third to one-quarter of that of ibuprofen 800 mg three times daily or naproxen 500 mg twice daily. Lumiracoxib was not associated with an increase in cardiovascular events.
AuthorsKatherine A Lyseng-Williamson, Monique P Curran
JournalDrugs (Drugs) Vol. 64 Issue 19 Pg. 2237-46; discussion 2247-8 ( 2004) ISSN: 0012-6667 [Print] New Zealand
PMID15456339 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Cyclooxygenase Inhibitors
  • Organic Chemicals
  • Pyrazoles
  • Sulfonamides
  • Diclofenac
  • Oxycodone
  • Celecoxib
  • lumiracoxib
Topics
  • Administration, Oral
  • Arthritis, Rheumatoid (drug therapy)
  • Celecoxib
  • Cyclooxygenase Inhibitors (metabolism, pharmacology, therapeutic use)
  • Diclofenac (analogs & derivatives)
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Evaluation, Preclinical (methods)
  • Female
  • Half-Life
  • Humans
  • Male
  • Molecular Structure
  • New Zealand
  • Organic Chemicals (adverse effects, metabolism, therapeutic use)
  • Osteoarthritis (drug therapy)
  • Oxycodone (pharmacology, therapeutic use)
  • Pain (drug therapy)
  • Pyrazoles (pharmacology, therapeutic use)
  • Sulfonamides (pharmacology, therapeutic use)
  • Terminology as Topic
  • World Health Organization

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: